This post was originally published on this site
Bonus BioGroup has completed a preliminary study of a new drug it developed to treat acute and life-threatening respiratory distress in COVID-19 patients, CEO Dr. Shai Meretzki told The Jerusalem Post. The drug MesenCure, which consists of activated …
Click here to read full article